Minimal Residual Disease in Melanoma:molecular characterization of in transit cutaneous metastases and Circulating Melanoma Cells recognizes an expression panel potentially related to disease progression

Paterlini-Brechot, 2007, Circulating tumour cells (CTC detection: clinical impact and future directions), Cancer Lett., 253, 180, 10.1016/j.canlet.2006.12.014 Mocellin, 2006, Circulating tumor cells: the ‘leukemic phase’ of solid cancers, Trends Mol. Med., 12, 130, 10.1016/j.molmed.2006.01.006 Ghossein, 1999, Molecular detection of micrometastases and circulating tumour cells in solid tumors, Clin. Cancer Res., 5, 1950 Luzzi, 1998, Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases, Am. J. Pathol., 153, 865, 10.1016/S0002-9440(10)65628-3 Haass, 2005, Adhesion, migration and communication in melanocytes and melanoma, Pigment Cell Res., 18, 150, 10.1111/j.1600-0749.2005.00235.x Mocellin, 2006, The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis, Clin. Cancer Res., 12, 4605, 10.1158/1078-0432.CCR-06-0823 Braeuer, 2014, Why is melanoma so metastatic?, Pigment Cell Melanoma Res., 27, 19, 10.1111/pcmr.12172 Kalluri, 2009, The basics of epithelial-mesenchymal transition, J. Clin. Invest., 119, 1420, 10.1172/JCI39104 Thiery, 2009, Epithelial-mesenchymal transitions in development and disease, Cell, 139, 871, 10.1016/j.cell.2009.11.007 Yu, 2013, Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition, Science, 339, 580, 10.1126/science.1228522 Okabe, 2014, CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma, Br. J. Cancer, 110, 958, 10.1038/bjc.2013.759 Satelli, 2015, Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response, Clin. Chem., 61, 259, 10.1373/clinchem.2014.228122 Lembessis, 2007, Clin. Chem. Lab. Med., 45, 1488, 10.1515/CCLM.2007.301 Tsouma, 2008, Circulating tumor cells in colorectal cancer: detection methods and clinical significance, Anticancer Res., 28, 3945 Panteleakou, 2009, Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance, Mol. Med., 15, 101, 10.2119/molmed.2008.00116 Theodoropoulos, 2010, Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer, Cancer Lett., 288, 99, 10.1016/j.canlet.2009.06.027 Ignatiadis, 2008, Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer, Clin. Cancer Res., 14, 2593, 10.1158/1078-0432.CCR-07-4758 Gaugler, 1994, Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes, J. Exp. Med., 179, 921, 10.1084/jem.179.3.921 Tsukamoto, 1992, A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase, EMBO J., 11, 519, 10.1002/j.1460-2075.1992.tb05082.x Mellado, 1999, Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients, Clin. Cancer Res., 5, 1843 Palmieri, 1999, Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group, J. Clin. Oncol., 17, 304, 10.1200/JCO.1999.17.1.304 Rose, 1986, Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence, Proc. Natl. Acad. Sci. U. S. A., 83, 1261, 10.1073/pnas.83.5.1261 Keilholz, 2004, Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction, Clin. Cancer Res., 10, 1605, 10.1158/1078-0432.CCR-0610-3 Ghossein, 1996, Polymerase chain reaction in the detection of micrometastases and circulating tumor cells, Cancer, 78, 10, 10.1002/(SICI)1097-0142(19960701)78:1<10::AID-CNCR3>3.0.CO;2-L Klinac, 2014, Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma, BMC Cancer, 14, 423, 10.1186/1471-2407-14-423 Rao, 2011, Circulating melanoma cells and survival in metastatic melanoma, Int. J. Oncol., 38, 755 Trzpis, 2007, Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule, Am. J. Pathol., 171, 386, 10.2353/ajpath.2007.070152 Yang, 2009, Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells, Biotechnol. Bioen., 102, 521, 10.1002/bit.22066 Chu, 2000, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases, Mod. Pathol., 13, 962, 10.1038/modpathol.3880175 Khoja, 2013, Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma, J. Invest. Dermatol., 133, 1582, 10.1038/jid.2012.468 Boiko, 2010, Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271, Nature, 466, 133, 10.1038/nature09161 Luo, 2014, Isolation and molecular characterization of circulating melanoma cells, Cell Rep., 7, 645, 10.1016/j.celrep.2014.03.039 Ishikawa, 2014, Laminins 411 and 421 differentially promote tumor cell migration via alpha6beta1 integrin and MCAM (CD146), Matrix Biol., 38, 69, 10.1016/j.matbio.2014.06.002 Ishikawa, 2014, Monoclonal antibodies to human laminin alpha4 chain globular domain inhibit tumor cell adhesion and migration on laminins 411 and 421, and binding of alpha6beta1 integrin and MCAM to alpha4-laminins, Matrix Biol., 36, 5, 10.1016/j.matbio.2014.03.003 Melnikova, 2006, Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8, Pigment Cell Res., 19, 395, 10.1111/j.1600-0749.2006.00331.x Rapanotti, 2013, Blood MUC-18/MCAM expression in melanoma patients: a suitable marker of poor outcome, Br. J. Dermatol., 169, 221, 10.1111/bjd.12295 Rapanotti, 2014, Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma, Arch. Dermatol. Res., 306, 527, 10.1007/s00403-014-1473-7 Rapanotti, 2017, Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146, Cell Death Discov., 3, 17, 10.1038/cddiscovery.2017.5 De Luca, 2017, The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis, Oncotarget, 9, 15520, 10.18632/oncotarget.14690 Alais, 2001, “HEMCAM/CD146 downregulates cell surface expression of beta1 integrins, J. Cell Sci., 114, 1847, 10.1242/jcs.114.10.1847 Stalin, 2017, MCAM and its isoforms as novel target in angiogenesis research and therapy, 429 Stalin, 2013, Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin, J. Biol. Chem., 288, 8991, 10.1074/jbc.M112.446518 Schatton, 2008, Identification of cells initiating human melanomas, Nature, 451, 345, 10.1038/nature06489 Wilson, 2014, ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit, Cancer Res., 74, 4196, 10.1158/0008-5472.CAN-14-0582 Kupas, 2011, RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells, J. Invest. Dermatol., 131, 944, 10.1038/jid.2010.377 Gray, 2015, Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment, J. Investig. Dermatol., 135, 2040, 10.1038/jid.2015.127 Chartrain, 2012, Melanoma chemotherapy leads to the selection of ABCB5-expressing cells, PloS ONE, 7, e36762, 10.1371/journal.pone.0036762 Laga, 2010, Cellular heterogeneity in vertical growth phase melanoma, Arch. Pathol. Lab. Med., 134, 1750, 10.5858/2009-0394-RAR.1 Hsu, 2008, Aggressive melanoma cells escape from BMP-7 mediated autocrine growth inhibition through coordinated Noggin upregulation, Lab. Invest., 88, 842, 10.1038/labinvest.2008.55 Balint, 2005, Activation of Notch1 signaling is required for b-catenin–mediated human primary melanoma progression, J. Clin. Invest., 115, 3166, 10.1172/JCI25001 Weeraratna, 2002, Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma, Cancer Cell, 1279 Frank, 2005, ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma, Cancer Res., 65, 4320, 10.1158/0008-5472.CAN-04-3327 Klein, 2007, Increased expression of stem cell markers in malignant melanoma, Mod. Pathol., 20, 102, 10.1038/modpathol.3800720 Rapanotti, 2020, Stem – Mesenchymal signature cell genes detected in heterogeneous circulating melanoma cells correlate with disease stage in melanoma patients, Front. Mol. Biosci., 10.3389/fmolb.2020.00092 Rapanotti, 2018, Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: a molecular panel to investigate disease progression, Mediterr. J. Hematol. Infect. Dis., 10 Balch, 2001, Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma, J. Clin. Oncol., 19, 3635, 10.1200/JCO.2001.19.16.3635 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Hazan, 2004, Cadherin switch in tumor progression, Ann. N. Y. Acad. Sci., 1014, 155, 10.1196/annals.1294.016 Silye, 1998, E-cadherin/catenin complex in benign and malignant melanocytic lesions, J. Pathol., 186, 350, 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K LehmannJ.M., HolzmannB., BreitbartE.W., SchmiegelowP., RiethmullerG., JohnsonJ.P. (1987). Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. 47:841–845. Xie, 1997, Expression of mcam/muc18 by human melanoma cells leads to increased tumor growth and metastasis, Cancer Res., 57, 2295 Ray, 1994, The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis, Eur. Respir. J., 7, 2062, 10.1183/09031936.94.07112062 Curry, 1996, Detection and quantitation of melanoma cells in the circulation of patients, Melanoma Res., 6, 45, 10.1097/00008390-199602000-00007 Schittek, 1999, Amplification of Melan A messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma, Br. J. Dermatol., 141, 30, 10.1046/j.1365-2133.1999.02917.x Chomczynski, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal. Biochem., 162, 156, 10.1016/0003-2697(87)90021-2 Murakami, 2004, Chemokine receptors and melanoma metastasis, J. Dermatol. Sci., 36, 71, 10.1016/j.jdermsci.2004.03.002 Swart, 2005, Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?, Cancer Metastasis Rev., 24, 223, 10.1007/s10555-005-1573-0 Simpson, 2005, Cancer/testis antigens, gametogenesis and cancer, Nat. Rev. Cancer, 5, 615, 10.1038/nrc1669 Velazquez, 2007, Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors, Cancer Immun., 7, 11 Rothhammer, 2007, Bone morphogenic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma, Cancer Biomark., 3, 111, 10.3233/CBM-2007-3205 Bonitsis, 2006, The role of cadherin/catenin complex in malignant melanoma, Exp. Oncol., 28, 187 Radford, 1996, CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma, Biochem. Biophys. Res. Commun., 222, 13, 10.1006/bbrc.1996.0690 Selzer, 2000, Erythropoietin receptor expression in human melanoma cells, Melanoma Res., 10, 421, 10.1097/00008390-200010000-00003 Djerf, 2009, ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839), Melanoma Res., 19, 156, 10.1097/CMR.0b013e32832c6339 de Bono, 2008, Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin. Cancer Res., 14, 6302, 10.1158/1078-0432.CCR-08-0872 Cohen, 2008, Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer, J. Clin. Oncol., 26, 3213, 10.1200/JCO.2007.15.8923 Cristofanilli, 2004, Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N. Engl. J. Med., 351, 781, 10.1056/NEJMoa040766 Quintana, 2010, Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized, Cancer Cell, 18, 510, 10.1016/j.ccr.2010.10.012 Zhao, 2019, Molecular detection of epithelial-mesenchymal transition markers un circulating tumour cell from pancreatic cancer patients: potential role in clinical practice, World J. Gastroenterol., 25138 Jolly, 2015, Implications of the hybrid epithelial/mesenchymal phenotype in metastasis, Front. Oncol., 5, 155, 10.3389/fonc.2015.00155 PastushenkoI., BrisebarreA., SifrimA., FioramontiM., RevencoT., BoumahdiS., et al.Identification of the tumour transition states occurring during EMT Nature. 2018; 556 (7702): 463–468. 10.1038/s41586-018-0040-3. Kröger, 2019, Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells, Proc. Natl. Acad. Sci. U. S. A., 116, 11553, 10.1073/pnas.1907473116 Shih, 1999, The role of CD146 (Mel-CAM) in biology and pathology, J. Pathol., 189, 4, 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P Bardin, 2001, Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion, Blood, 98, 3677, 10.1182/blood.V98.13.3677 Delorme, 2008, Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells, Blood, 111, 2631, 10.1182/blood-2007-07-099622 Guezguez, 2007, Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor, J. Immunol., 179, 6673, 10.4049/jimmunol.179.10.6673 Sacchetti, 2007, Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment, Cell, 131, 324, 10.1016/j.cell.2007.08.025 Zabouo, 2009, CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines, Breast Cancer Res., 11, 1, 10.1186/bcr2215 Onstenk, 2015, Improved circulating tumor cell detection by a combined EpCAM and MCAM cell search enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy, Smit. Mol. Cancer Ther., 14, 821, 10.1158/1535-7163.MCT-14-0653 Elliott, 2009, ABCB5 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome, Mol. Cancer Res., 7, 79, 10.1158/1541-7786.MCR-08-0235 Aya-Bonilla, 2019, Immunomagnetic-enriched subpopulationsof melanoma circulating tumour cells (CTCs) exhinit distinct transcriptome profiles, Cancer, 157, 1